Lipid nanoparticles for local delivery of mRNA to the respiratory tract : Effect of PEG-lipid content and administration route
(2024) In European Journal of Pharmaceutics and Biopharmaceutics 198.- Abstract
Design of inhalable mRNA therapeutics is promising because local administration in the respiratory tract is minimally invasive and induces a local response. However, several challenges related to administration via inhalation and respiratory tract barriers have so far prevented the progress of inhaled mRNA therapeutics. Here, we investigated factors of importance for lipid nanoparticle (LNP)-mediated delivery of mRNA to the respiratory tract. We hypothesized that: (i) the PEG-lipid content is important for providing colloidal stability during aerosolization and for mucosal delivery, (ii) the PEG-lipid content influences the expression of mRNA-encoded protein in the lungs, and (iii) the route of administration (nasal versus pulmonary)... (More)
Design of inhalable mRNA therapeutics is promising because local administration in the respiratory tract is minimally invasive and induces a local response. However, several challenges related to administration via inhalation and respiratory tract barriers have so far prevented the progress of inhaled mRNA therapeutics. Here, we investigated factors of importance for lipid nanoparticle (LNP)-mediated delivery of mRNA to the respiratory tract. We hypothesized that: (i) the PEG-lipid content is important for providing colloidal stability during aerosolization and for mucosal delivery, (ii) the PEG-lipid content influences the expression of mRNA-encoded protein in the lungs, and (iii) the route of administration (nasal versus pulmonary) affects mRNA delivery in the lungs. In this study, we aimed to optimize the PEG-lipid content for mucosal delivery and to investigate the effect of administration route on the kinetics of protein expression. Our results show that increasing the PEG-lipid content improves the colloidal stability during the aerosolization process, but has a negative impact on the transfection efficiency in vitro. The kinetics of protein expression in vivo is dependent on the route of administration, and we found that pulmonary administration of mRNA-LNPs to mice results in more durable protein expression than nasal administration. These results demonstrate that the design of the delivery system and the route of administration are important for achieving high mRNA transfection efficiency in the respiratory tract.
(Less)
- author
- Ongun, Melike ; Lokras, Abhijeet Girish ; Baghel, Saahil ; Shi, Zhenning ; Schmidt, Signe Tandrup ; Franzyk, Henrik ; Rades, Thomas ; Sebastiani, Federica LU ; Thakur, Aneesh and Foged, Camilla
- organization
- publishing date
- 2024-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lipid nanoparticle, mRNA therapeutics, Mucosal delivery, Nanomedicine, Pulmonary/nasal administration, Vaccine
- in
- European Journal of Pharmaceutics and Biopharmaceutics
- volume
- 198
- article number
- 114266
- publisher
- Elsevier
- external identifiers
-
- scopus:85189507070
- pmid:38499255
- ISSN
- 0939-6411
- DOI
- 10.1016/j.ejpb.2024.114266
- language
- English
- LU publication?
- yes
- id
- c39bfcaa-dc03-43da-b411-12af02946532
- date added to LUP
- 2024-04-25 10:23:54
- date last changed
- 2024-06-20 15:34:21
@article{c39bfcaa-dc03-43da-b411-12af02946532,
abstract = {{<p>Design of inhalable mRNA therapeutics is promising because local administration in the respiratory tract is minimally invasive and induces a local response. However, several challenges related to administration via inhalation and respiratory tract barriers have so far prevented the progress of inhaled mRNA therapeutics. Here, we investigated factors of importance for lipid nanoparticle (LNP)-mediated delivery of mRNA to the respiratory tract. We hypothesized that: (i) the PEG-lipid content is important for providing colloidal stability during aerosolization and for mucosal delivery, (ii) the PEG-lipid content influences the expression of mRNA-encoded protein in the lungs, and (iii) the route of administration (nasal versus pulmonary) affects mRNA delivery in the lungs. In this study, we aimed to optimize the PEG-lipid content for mucosal delivery and to investigate the effect of administration route on the kinetics of protein expression. Our results show that increasing the PEG-lipid content improves the colloidal stability during the aerosolization process, but has a negative impact on the transfection efficiency in vitro. The kinetics of protein expression in vivo is dependent on the route of administration, and we found that pulmonary administration of mRNA-LNPs to mice results in more durable protein expression than nasal administration. These results demonstrate that the design of the delivery system and the route of administration are important for achieving high mRNA transfection efficiency in the respiratory tract.</p>}},
author = {{Ongun, Melike and Lokras, Abhijeet Girish and Baghel, Saahil and Shi, Zhenning and Schmidt, Signe Tandrup and Franzyk, Henrik and Rades, Thomas and Sebastiani, Federica and Thakur, Aneesh and Foged, Camilla}},
issn = {{0939-6411}},
keywords = {{Lipid nanoparticle; mRNA therapeutics; Mucosal delivery; Nanomedicine; Pulmonary/nasal administration; Vaccine}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{European Journal of Pharmaceutics and Biopharmaceutics}},
title = {{Lipid nanoparticles for local delivery of mRNA to the respiratory tract : Effect of PEG-lipid content and administration route}},
url = {{http://dx.doi.org/10.1016/j.ejpb.2024.114266}},
doi = {{10.1016/j.ejpb.2024.114266}},
volume = {{198}},
year = {{2024}},
}